CIFFABA Trademark

Trademark Overview

On Friday, April 12, 2019, a trademark application was filed for CIFFABA with the United States Patent and Trademark Office. The USPTO has given the CIFFABA trademark a serial number of 88383895. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 31, 2022. This trademark is owned by Pfizer Inc.. The CIFFABA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
ciffaba

General Information

Serial Number88383895
Word MarkCIFFABA
Filing DateFriday, April 12, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 31, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 30, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 1, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, October 31, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, October 31, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, January 25, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 24, 2022SOU EXTENSION 5 GRANTED
Wednesday, January 19, 2022SOU EXTENSION 5 FILED
Wednesday, January 19, 2022SOU TEAS EXTENSION RECEIVED
Friday, August 20, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 18, 2021SOU EXTENSION 4 GRANTED
Wednesday, August 18, 2021SOU EXTENSION 4 FILED
Wednesday, August 18, 2021SOU TEAS EXTENSION RECEIVED
Thursday, February 11, 2021ITU LETTER MAILED, NO RESPONSE REQUIRED
Thursday, February 11, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, January 30, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 28, 2021SOU TEAS EXTENSION RECEIVED
Thursday, January 28, 2021SOU EXTENSION 3 GRANTED
Thursday, January 28, 2021SOU EXTENSION 3 FILED
Thursday, January 28, 2021SOU TEAS EXTENSION RECEIVED
Thursday, September 10, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 8, 2020SOU EXTENSION 2 GRANTED
Tuesday, September 8, 2020SOU EXTENSION 2 FILED
Tuesday, September 8, 2020SOU TEAS EXTENSION RECEIVED
Thursday, February 6, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 4, 2020SOU EXTENSION 1 GRANTED
Tuesday, February 4, 2020SOU EXTENSION 1 FILED
Tuesday, February 4, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, January 28, 2020CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Monday, January 27, 2020ASSIGNED TO LIE
Monday, January 13, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, September 24, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 30, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 30, 2019PUBLISHED FOR OPPOSITION
Wednesday, July 10, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 19, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 12, 2019ASSIGNED TO EXAMINER
Wednesday, May 1, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 16, 2019NEW APPLICATION ENTERED

Related Keywords

ciffaba preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological